Abbott India Reports ₹415.3 Crore Net Profit in Q2 FY26; Revenue Up 7.7%

Abbott India announced its Q2 FY26 results on November 6, reporting higher profitability and improved operating margins supported by steady revenue growth.

Key Financial Highlights for Q2 FY26

• Net Profit: ₹415.3 crore, up 16% YoY from ₹359 crore
• Revenue: ₹1,757 crore, up 7.7% YoY from ₹1,633 crore
• EBITDA: ₹502.6 crore, up 14.5% YoY from ₹439 crore
• EBITDA Margin:6% vs 26.9% in Q2 FY25

The margin expansion reflects improved operational efficiency during the quarter.

Q1 FY26 Performance Recap

• Net Profit: Up 11.6% YoY
• EBITDA: ₹445.7 crore, up 14% YoY
• EBITDA Margin:6% vs 25.1% in Q1 FY25

Sequential improvement in margins indicates consistent operating performance across the first half of FY26.

Operational Overview

Abbott India attributed growth to strong demand across therapeutic segments and cost optimisation measures. The company continues to focus on expanding its product portfolio and maintaining efficiency in operations.

Abbott India Share Price Performance

On November 6, 2025, Abbott India share price opened at ₹29,400.00, compared to the previous close of ₹29,360.00. During the session, the stock touched a high of ₹30,490.00 and a low of ₹29,260.00 before closing at ₹29,500.00, up by 0.48% at the end of the trading day.

The stock recorded a traded volume of 0.55 lakh shares and a traded value of ₹165.16 crore on the NSE. The market capitalisation stood at ₹62,685.44 crore. Over the past 52 weeks, Abbott India has hit a high of ₹37,000.00 and a low of ₹25,325.00. The stock’s P/E ratio is 44.

Read More: Zepto Launches 10-Minute Medicine Delivery.

Conclusion

Abbott India delivered improved profitability and margin expansion in Q2 FY26, supported by steady revenue growth and operational efficiency. The company remains focused on sustaining growth momentum through portfolio diversification and cost management.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.